Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Simple Summary The genomics-based concept of precision medicine began to emerge
following the completion of the Human Genome Project. In contrast to evidence-based …

Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-
adapted based on clinical features, leukemia genomics and minimal residual disease …

Patient-derived organoids (PDOs) can model personalized therapy responses; however,
current screening technologies cannot reveal drug response mechanisms or how tumor …

Patient-derived organoids resemble the biology of tissues and tumors, enabling ex vivo
modeling of human diseases. They have heterogeneous morphologies with unclear …

Systematically identifying synergistic combinations of targeted agents and immunotherapies
for cancer treatments remains difficult. In this study, we integrated high-throughput and high …

Cancer therapies trigger diverse cellular responses, ranging from apoptotic death to
acquisition of persistent therapy-refractory states such as senescence. Tipping the balance …

Background Patients with colorectal metastatic disease have a poor prognosis, limited
therapeutic options, and frequent development of resistance. Strategies based on tumor …

Basic and clinical cancer research requires tumor models that consistently recapitulate the
characteristics of prima tumors. As ex vivo 3D cultures of patient tumor cells, patient‐derived …

The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia
(AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment …